docetaxel anhydrous: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
docetaxel anhydrous: clinical details
Prescribing considerations
- Restrict use to specialist cytotoxic chemotherapy units under an appropriately qualified clinician.
- Ensure indicated corticosteroid premedication has been prescribed and taken unless contraindicated.
- Assess hepatic function, baseline haematology, infection risk, fluid retention, pulmonary disease, neuropathy, and previous paclitaxel hypersensitivity.
- Consider regimen-specific G-CSF prophylaxis and contraindications of every accompanying anticancer medicine.
- Account for the formulation's ethanol content in liver disease, epilepsy, alcohol dependence, pregnancy, and other susceptible groups.
Contraindications and cautions
- Hypersensitivity to docetaxel or any excipient
- Baseline neutrophil count below the product threshold
- Severe hepatic impairment
- Any contraindication applying to medicines used in combination
Monitoring
- Full blood count before treatment and continued assessment for neutropenia, infection, anaemia, and thrombocytopenia
- Liver function at baseline and before subsequent treatment
- Close observation for hypersensitivity, particularly during early infusions
- Assess gastrointestinal toxicity, pulmonary symptoms, fluid retention, severe skin reactions, neuropathy, visual symptoms, and cardiac symptoms
- Monitor clinically for tumour lysis syndrome in susceptible patients
Clinical pharmacology
A taxane that promotes microtubule assembly and inhibits disassembly. It is metabolised mainly through CYP3A pathways, is highly protein-bound, and is eliminated predominantly in faeces as metabolites.
Formulation and product differences
- This is a single-vial concentrate that does not require prior dilution with a separate solvent before addition to an infusion vehicle.
- It contains polysorbate 80, ethanol anhydrous, and citric acid.
- Preparation instructions must not be substituted with those for two-vial docetaxel products.
- The vial is single-use; prepared solution must be inspected and discarded if crystals or precipitate appear.
docetaxel anhydrous preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 20 mg/mL
docetaxel anhydrous interactions
Give the oncology pharmacist a complete list of prescribed, non-prescribed, and complementary products. Important examples include:
Strong CYP3A4 inhibitors, including clarithromycin, itraconazole, ketoconazole, ritonavir, and voriconazole
They can reduce docetaxel metabolism and increase toxicity, so avoidance or close specialist surveillance may be required.
Ciclosporin and erythromycin
They may alter CYP3A-mediated docetaxel metabolism and require specialist review.
Other medicines affected by alcohol
The ethanol in this formulation may modify their effects and contribute to central nervous system impairment.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.